A61K 39/00116
Serine proteases
Official title: {Serine proteases, e.g. kallikrein}
A61K39/00116 (Serine proteases) appears on 5 US grants and 17 published applications in this corpus.
Search patents in A61K- Granted patents
- 5
- Published applications
- 17
- Assignees
- 10
- Inventors
- 42
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2018 | 0 | 2 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 3 |
| 2022 | 2 | 3 |
| 2023 | 1 | 3 |
| 2024 | 1 | 3 |
| 2025 | 0 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for metal containing formulations capable of modulating immune response12 May 2026US 12,622,922 B2The Regents of the University of Michigan
- Compositions and method for optimized peptide vaccines using residue optimization20 Aug 2024US 12,064,475 B2Think Therapeutics, Inc.
- Compositions and method for optimized peptide vaccines using residue optimization13 Jun 2023US 11,672,850 B2Think Therapeutics, Inc.
- Compositions and method for optimized peptide vaccines using residue optimization11 Oct 2022US 11,464,842 B1Think Therapeutics, Inc.
- Arenavirus particles as cancer vaccines8 Mar 2022US 11,266,727 B2Hookipa Biotech GmbH
- Compositions and method for optimized peptide vaccines using residue optimization3 Jul 2025US 2025/0213643 A1Think Therapeutics, Inc.
- Tissue-specific antigens for cancer immunotherapy16 May 2024US 2024/0156961 A1Biontech US Inc.
- Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use14 Mar 2024US 2024/0084042 A1Genentech, Inc.
- Rna encoding a tumor antigen7 Mar 2024US 2024/0075116 A1CureVac AG
- Compositions and method for optimized peptide vaccines using residue optimization16 Nov 2023US 2023/0364212 A1Think Therapeutics, Inc.
Most cited
By later US patents
- Compositions and method for optimized peptide vaccines using residue optimization6US 11,464,842 B1Think Therapeutics, Inc. · 2022
- Compositions and method for optimized peptide vaccines using residue optimization5US 11,672,850 B2Think Therapeutics, Inc. · 2023
- Arenavirus particles as cancer vaccines3US 11,266,727 B2Hookipa Biotech GmbH · 2022